Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Financing Activities (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Cash from Financing Activities readings, the most recent being -$1681.0 for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities changed N/A to -$1681.0 in Q1 2026 year-over-year; TTM through Jan 2026 was -$1.8 million, a 1.55% decrease, with the full-year FY2025 number at -$1.8 million, down 1.03% from a year prior.
  • Cash from Financing Activities hit -$1681.0 in Q1 2026 for Pharma-Bio Serv, up from -$9202.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of -$792.0 in Q4 2023 to a low of -$1.8 million in Q1 2022.
  • Median Cash from Financing Activities over the past 5 years was -$8197.5 (2024), compared with a mean of -$626663.6.
  • Biggest five-year swings in Cash from Financing Activities: crashed 62248.3% in 2022 and later soared 66.71% in 2023.
  • Pharma-Bio Serv's Cash from Financing Activities stood at -$2379.0 in 2022, then skyrocketed by 66.71% to -$792.0 in 2023, then tumbled by 120.58% to -$1747.0 in 2024, then tumbled by 426.73% to -$9202.0 in 2025, then skyrocketed by 81.73% to -$1681.0 in 2026.
  • The last three reported values for Cash from Financing Activities were -$1681.0 (Q1 2026), -$9202.0 (Q4 2025), and -$5004.0 (Q3 2025) per Business Quant data.